Literature DB >> 26239990

Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.

Suzanne L Parker1, Frantzeska Frantzeskaki2, Steven C Wallis1, Chryssa Diakaki2, Helen Giamarellou3, Despoina Koulenti4, Ilias Karaiskos3, Jeffrey Lipman5, George Dimopoulos2, Jason A Roberts6.   

Abstract

This study describes the population pharmacokinetics of fosfomycin in critically ill patients. In this observational study, serial blood samples were taken over several dosing intervals of intravenous fosfomycin treatment. Blood samples were analyzed using a validated liquid chromatography-tandem mass spectrometry technique. A population pharmacokinetic analysis was performed using nonlinear mixed-effects modeling. Five hundred fifteen blood samples were collected over one to six dosing intervals from 12 patients. The mean (standard deviation) age was 62 (17) years, 67% of patients were male, and creatinine clearance (CLCR) ranged from 30 to 300 ml/min. A two-compartment model with between-subject variability on clearance and volume of distribution of the central compartment (Vc) described the data adequately. Calculated CLCR was supported as a covariate on fosfomycin clearance. The mean parameter estimates for clearance on the first day were 2.06 liters/h, Vc of 27.2 liters, intercompartmental clearance of 19.8 liters/h, and volume of the peripheral compartment of 22.3 liters. We found significant pharmacokinetic variability for fosfomycin in this heterogeneous patient sample, which may be explained somewhat by the observed variations in renal function.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26239990      PMCID: PMC4576076          DOI: 10.1128/AAC.01321-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models.

Authors:  J Parke; N H Holford; B G Charles
Journal:  Comput Methods Programs Biomed       Date:  1999-04       Impact factor: 5.428

2.  Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.

Authors:  Mieke Carlier; Michaël Noë; Jan J De Waele; Veronique Stove; Alain G Verstraete; Jeffrey Lipman; Jason A Roberts
Journal:  J Antimicrob Chemother       Date:  2013-06-25       Impact factor: 5.790

3.  Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*.

Authors:  Andrew A Udy; João P Baptista; Noelle L Lim; Gavin M Joynt; Paul Jarrett; Leesa Wockner; Robert J Boots; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

4.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.

Authors:  J L Vincent; R Moreno; J Takala; S Willatts; A De Mendonça; H Bruining; C K Reinhart; P M Suter; L G Thijs
Journal:  Intensive Care Med       Date:  1996-07       Impact factor: 17.440

5.  A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: application to a pilot pharmacokinetic study in humans.

Authors:  Suzanne L Parker; Jeffrey Lipman; Jason A Roberts; Steven C Wallis
Journal:  J Pharm Biomed Anal       Date:  2014-11-30       Impact factor: 3.935

6.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

7.  Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.

Authors:  Konstantinos Pontikis; Ilias Karaiskos; Styliani Bastani; George Dimopoulos; Michalis Kalogirou; Maria Katsiari; Angelos Oikonomou; Garyphallia Poulakou; Emmanuel Roilides; Helen Giamarellou
Journal:  Int J Antimicrob Agents       Date:  2013-10-16       Impact factor: 5.283

Review 8.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

Review 9.  How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?

Authors:  T W Felton; W W Hope; J A Roberts
Journal:  Diagn Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 2.803

10.  Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

Authors:  Mieke Carlier; Sofie Carrette; Jason A Roberts; Veronique Stove; Alain Verstraete; Eric Hoste; Pieter Depuydt; Johan Decruyenaere; Jeffrey Lipman; Steven C Wallis; Jan J De Waele
Journal:  Crit Care       Date:  2013-05-03       Impact factor: 9.097

View more
  18 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients.

Authors:  Mojdeh S Heavner; Kimberly C Claeys; Anne M Masich; Jeffrey P Gonzales
Journal:  Curr Infect Dis Rep       Date:  2018-04-05       Impact factor: 3.725

Review 2.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 3.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

Review 4.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

5.  Semi-mechanistic PK/PD modelling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii.

Authors:  S Mohd Sazlly Lim; A J Heffernan; J A Roberts; F B Sime
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

6.  Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.

Authors:  James Albiero; Josmar Mazucheli; Juliana Pimenta Dos Reis Barros; Marcia Maria Dos Anjos Szczerepa; Sheila Alexandra Belini Nishiyama; Floristher Elaine Carrara-Marroni; Serubbabel Sy; Matthew Fidler; Sherwin K B Sy; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

7.  High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients.

Authors:  D Busse; P Simon; D Petroff; N El-Najjar; L Schmitt; D Bindellini; A Dietrich; M Zeitlinger; W Huisinga; R Michelet; H Wrigge; C Kloft
Journal:  Antimicrob Agents Chemother       Date:  2022-05-23       Impact factor: 5.938

8.  Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.

Authors:  Matteo Rinaldi; Pier Giorgio Cojutti; Eleonora Zamparini; Sara Tedeschi; Nicolò Rossi; Matteo Conti; Maddalena Giannella; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

9.  Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.

Authors:  James Albiero; Sherwin K B Sy; Josmar Mazucheli; Silvana Martins Caparroz-Assef; Bruno Buranello Costa; Janio Leal Borges Alves; Ana Cristina Gales; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

10.  Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

Authors:  Sander G Kuiper; Anneke C Dijkmans; Erik B Wilms; Ingrid M C Kamerling; Jacobus Burggraaf; Jasper Stevens; Cees van Nieuwkoop
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.